GastroenterologyNews.net

Gastroenterology Xagena

Anti-TNF therapy in patients with antibiotic refractory pouchitis or Crohn's-like complications of the pouch


Data about the effectiveness of biologics, including anti-tumor necrosis factor ( anti-TNF ) therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn's disease-associated pouch complications are sparse.

Researchers have performed a systematic review of the literature.

A total of 17 papers and 2 abstracts was identified, most of these retrospective case series, including a total of 192 patients treated either with Infliximab [ Remicade ] ( n=140 ) or Adalimumab [ Humira ] ( n=52 ).

No reports were found for anti-integrin therapies or other anti-TNF agents such as Certolizumab pegol or Golimumab.

Because of the heterogeneity of the studies, small numbers of patients, differing cotreatments, and subjective outcome definitions, the exact efficacy of these biological therapies cannot be assessed in a combined fashion.

Overall Infliximab appears to have good clinical effectiveness in selected patients achieving up to 80% short-term and around 50% long-term response, whereas the few data available for Adalimumab are not sufficient to draw valid conclusions.

Larger prospectively collected multicenter data with clearly defined inclusion criteria and outcomes are necessary to better define the clinical value of anti-TNF therapy in patients with antibiotic refractory pouchitis or Crohn's-like complications of the pouch. ( Xagena )

Herfarth HH et al, J Clin Gastroenterol 2015; Epub ahead of print

XagenaMedicine_2015



Indietro